Skip to main content
SpringerLink
Log in
Book cover

Tamoxifen pp 43–58Cite as

Interactions of Tamoxifen with Lipid Signal Transduction Cascades

  • Chapter

Abstract

Triphenylethylenes are extremely useful drugs with therapeutic potential beyond breast cancer. In light of this broad utility we must also begin to address important questions regarding Tamoxifen side effects, as concern has been expressed for participants in prophylactic clinical trials, and for those already taking Tamoxifen for breast cancer (Fisher et al., 1994; Magriples et al., 1993). The multiple effects of Tamoxifen certainly indicate the need for more intensive studies on cell-specific actions of this drug and related synthetic antiestrogen-based agents. Elucidation of nongenomic pathways of triphenylethylene action is key to understanding the multimodal effects of these molecules.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Berman E, McBride M, Tong W (1994): Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines. Leukemia 8: 1191–6

    PubMed  CAS  Google Scholar 

  • Bignon E, Pons M, DorÄ JC, Gilbert J, Ojasoo T, Miquel JF, Raynaud JP, de Paul et AC (1991): Influence of di- and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis. Biochem Pharmacol 42:1373–1383

    Article  PubMed  CAS  Google Scholar 

  • Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA (1992): Induction of transforming growth factor ß 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52:4261–4264

    PubMed  CAS  Google Scholar 

  • Cabot MC, Welsh CJ, Zhang Z, Cao H (1989): Evidence for a protein kinase C-directed mechanism in the phorbol diester-induced phospholipase D pathway of diacylglycerol generation from phosphatidylcholine. FEBS Lett 245:85–90

    Article  PubMed  CAS  Google Scholar 

  • Cabot MC, Zhang Z, Giuliano AE (1995): Tamoxifen elicits rapid transmembrane lipid signal responses in human breast cancer cells. Breast Cancer Res Treat 36:299–306

    Article  PubMed  CAS  Google Scholar 

  • Callaghan R, Higgins CF (1995): Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 71:294–299

    Article  PubMed  CAS  Google Scholar 

  • Charlier C, Chariot A, Antoine N, Merville M-P, Gielen J, Castronovo V (1995): Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochem Pharmacol 49:351–358

    Article  PubMed  CAS  Google Scholar 

  • Cheng AL, Yeh KH, Luo YJ, Chuang SE, Chen DS (1995): Synergistic effect of doxorubicin and tamoxifen in the treatment of hepatocellular carcinoma (HCC): in vitro and pilot clinical studies. Proc Am Assoc Cancer Res 36:347 Abst #2065

    Google Scholar 

  • Coezy E, Borgna JL, Rochefort H (1982): Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.Cancer Res 42:317–323

    PubMed  CAS  Google Scholar 

  • Colletta AA, Wakefiels LM, Howell FV, van Roozendaal KEP, Danielpour D, Ebbs SR, Sporn MB, Baum M (1990): Antioestrogens induce the secretion of active transforming growth factor-ß from human fetal fibroblasts. Br J Cancer 62: 405–409

    Article  PubMed  CAS  Google Scholar 

  • Couldwell WT, Antel JP, Yong VW (1992): Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31:717–724

    Article  PubMed  CAS  Google Scholar 

  • Dallenbach-Hellweg G, Hahn U (1995): Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens.Int J Gynecol Pathol 14(1):7–15

    Article  PubMed  CAS  Google Scholar 

  • Darbon JM, Valette A, Bayard F (1986): Phorbol esters inhibit the proliferation of MCF-7 cells: possible implication of protein kinase C. Biochem Pharmacol 35:2683–2686

    Article  PubMed  CAS  Google Scholar 

  • Del Prete SA, Maurer LH, O’Donnell J, Jackson Forcier R, Le Marbre P (1984): Combination chemotherapy with cisplatin, carmustine, dacabarzine and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403–1405

    PubMed  CAS  Google Scholar 

  • Divecha N, Irvine RF (1995): Phospholipid signaling. Cell 80:269–278

    Article  PubMed  CAS  Google Scholar 

  • Doige CA, Yu X, Sharom FJ (1993): The effects of lipids and detergents on ATPase-active P-glycoprotein.Biochim Biophys Acta 1146:65–72

    Article  PubMed  CAS  Google Scholar 

  • Ecker RL, Katzenellenbogen BS (1983): Physical properties of estrogen receptor complexes in MCF-7 human breast cancer cells. J Biol Chem 257:8840–8846

    Google Scholar 

  • Exton JH (1994): Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1212:26–42

    PubMed  CAS  Google Scholar 

  • Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994): Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–527

    Article  PubMed  CAS  Google Scholar 

  • Gagliardi A, Collins DC (1993): Inhibition of angiogenesis by antiestrogens. Cancer Res 53:533–535

    PubMed  CAS  Google Scholar 

  • Haran EF, Maretzek AF, Goldberg I, Horowitz A, Degani H (1994): Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 54:5511 -5514

    PubMed  CAS  Google Scholar 

  • Hasmann M, Rattel B, Loser R (1994): Preclinical data for droloxifene. Cancer Lett 84:101–116

    Article  PubMed  CAS  Google Scholar 

  • Horgan K, Cooke E, Hallett MB, Mansel RE (1986): Inhibition of protein kinase C mediated signal transduction by tamoxifen. Biochem Pharmacol 35:4463–4465

    Article  PubMed  CAS  Google Scholar 

  • Hotta T, Tanimura H, Yamaue H, Iwahashi H, Tsunoda T, Tani M, Tamai M, Noguchi K, Mizobata S, Arii K, Terasawa H (1995): Adriamycin-resistance induced by P-glycoprotein is overcome by tamoxifen and cepharanthin. Proc Am Assoc Cancer Res 36:339 Abstr #2016

    Google Scholar 

  • Huang C, Cabot MC (1990): Phorbol diesters stimulate the accumulation of phosphatidate, phosphatidylethanol, and diacylglycerol in three cell types. J Biol Chem 265:14858–14863

    PubMed  CAS  Google Scholar 

  • Huang C, Cabot MC (1990): Vasopressin-induced polyphosphoinositide and phosphatidylcholine degradation in fibroblasts: temporal relationship for formation of phospholipase C and phopholipase D hydrolysis products. J Biol Chem 265:17468–17473

    PubMed  CAS  Google Scholar 

  • Issandou M, Bayard F, Darbon JM (1988): Inhibition of MCF-7 cell growth by 12-O-tetradecanoy lphorbol-13 -acetate and 1,2-dioctanoy 1-sn-glycerol: distinct effects of protein kinase C activity. Cancer Res 48:6943–6950

    PubMed  CAS  Google Scholar 

  • Issandou M, Darbon JM (1988): 1,2-Dioctanoylglycerol induces a discrete but transient translocation of protein kinase C as well as the inhibition of MCF-7 cell proliferation. Biochem Biophys Res Commun 151:458–465

    Article  PubMed  CAS  Google Scholar 

  • Issandou M, Faucher C, Bayard F, Darbon JM (1990): Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. Cancer Res 50:5845–5850

    PubMed  CAS  Google Scholar 

  • Johnston SRD, Haynes BP, Sacks NPM, McKinna JA, Griggs LJ, Jarman M, Baum M, Smith IE, Dowsett M (1993): Effect of estrogen receptor status and time on the intra-tumoral accumulation of tamoxifen and N-desmethyltamoxifen following short term therapy in human primary breast cancer. Breast Cancer Res Treat 28:241–250

    Article  PubMed  CAS  Google Scholar 

  • Kawamura I, Lacey E, Mizota T, Tsujimoto S, Nishigaki F, Manda T, Shimomura K (1994): The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells. Anticancer Res 14:427–431

    PubMed  CAS  Google Scholar 

  • Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD (1995): Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinol 136:2435–2441

    Article  CAS  Google Scholar 

  • Kirk J, Syed SK, Harris AL, Jarman M, Roufogalis BD, Stratford IJ, Carmichael J (1994): Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochem Pharmacol 48:277–285

    Article  PubMed  CAS  Google Scholar 

  • Lindner DJ, Borden EC (1995): An interferon ß and tamoxifen combination induces regression of established NIH-OVCAR-3 human ovarian carcinoma tumors in nude mice. Proc Am Assoc Cancer Res 36:264 Abstr #1575

    Google Scholar 

  • Love RR (1995): Tamoxifen chemoprevention: public health goals, toxicities for all and benefits to a few. Ann Oncol 6:127–128

    PubMed  CAS  Google Scholar 

  • Magriples U, Naftolin F, Schwartz PE, Carcangiu ML (1993): High-grade endometrial carcinoma in Tamoxifen-treated breast cancer patients. J Clin Oncol 11:485–490

    PubMed  CAS  Google Scholar 

  • McClay EF, Albright KD, Jones JA, Christen RD, Howell SB (1993): Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 53:1571–1576

    PubMed  CAS  Google Scholar 

  • McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D (1989): The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 63:1292–1295

    Article  PubMed  CAS  Google Scholar 

  • Nishizuka Y (1995): Protein kinase C and lipid signaling for sustained cellular responses. FASEB 9:484–496

    CAS  Google Scholar 

  • O’Brian CA, Liskamp RM, Solomon DH, Weinstein B (1985): Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462–2465

    PubMed  Google Scholar 

  • Rabinowicz AL, Hinton DR, Dyck P, Couldwell WT (1995): High-dose tamoxifen in treatment of brain tumors: Interaction with antiepileptic drugs. Epilepsia 36:513–515

    Article  PubMed  CAS  Google Scholar 

  • Ramu A, Glaubiger D, Magrath T, Joshi A (1983): Plasma membrane lipid structural order in doxorubicin-sensitive and -resistant P388 cells. Cancer Res 43:5533–5537

    PubMed  CAS  Google Scholar 

  • Ramu A, Ramu N, Rosario L (1991): Circumvention of multidrug-resistance in P388 cells is associated with a rise in the cellular content of phosphatidylcholine. Biochem Pharmacol 41:1455–1461

    Article  PubMed  CAS  Google Scholar 

  • Rauschning W, Pritchard KI (1994): Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat 31:83–94

    Article  PubMed  CAS  Google Scholar 

  • Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A (1995): Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem Pharmacol 50:723–726

    Article  PubMed  CAS  Google Scholar 

  • Ruetz A, Gros P (1994): Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77:1071–1081

    Article  PubMed  CAS  Google Scholar 

  • Sasco AJ, Raffi F, Satge D, Goburdhun J, Fallouh B, Leduc B (1995): Endometrial mullerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int J Gynaecol Obstet 48:307–310

    Article  PubMed  CAS  Google Scholar 

  • Smith DC, Trump DL (1994): A phase I trial of high-dose oral tamoxifen and CHOPE. Cancer Chemother Pharmacol 35:65–68

    Article  Google Scholar 

  • Vertosick FT Jr, Selker RG, Randall MS, Kristofik MP, Rehn T (1994): A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol 19:97–103

    Article  Google Scholar 

  • Warso MA, Menini P, Das Gupta TK (1995): Synergistic effect of tamoxifen on cisplatinum toxicity.Proc Am Assoc Cancer Res 36:346 Abstr #2058

    Google Scholar 

  • Welsh CJ, Yeh GC, Phang JM (1994): Increased phospholipase D activity in multidrug resistant breast cancer cells. Biochem Biophys Res Comm 202:211–217

    Article  PubMed  CAS  Google Scholar 

  • Wen Y, Cabot MC, Clauser E, Bürsten SL, Nadler JL (1995): Angiotensin II activated lipid signal transduction pathways in angiotensin II type 1 receptor transfected fibroblasts. Am J Physiol 269:435–442

    Google Scholar 

  • Wiseman H (1994): Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trend Pharmacol Sci 151:83–89

    Article  Google Scholar 

  • Wiseman H, Cannon M, Arnstein HR, Halliwell B (1993): Tamoxifen inhibits lipid peroxidation in cardiac microsomes. Comparison with liver microsomes and potential relevance to the cardiovascular benefits associated with cancer prevention and treatment by tamoxifen. Biochem Pharmacol 45:1851–1855

    Article  PubMed  CAS  Google Scholar 

  • Yeh GC, Lopaczynska J, Poore CM, Poore CM, Phang JM (1992): A new functional role for P-glycoprotein: efflux pump for Benzo(a)pyrene in human breast cancer MCF-7 cells. Cancer Res 2:6692–6695

    Google Scholar 

Download references

Authors
  1. Myles C. Cabot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Armando E. Giuliano
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 89 Rameau Drive, Toronto, Ontario, M2H 1T6, Canada

    John A. Kellen

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Birkhäuser Boston

About this chapter

Cite this chapter

Cabot, M.C., Giuliano, A.E. (1996). Interactions of Tamoxifen with Lipid Signal Transduction Cascades. In: Kellen, J.A. (eds) Tamoxifen. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4092-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-4092-1_3

  • Publisher Name: Birkhäuser Boston

  • Print ISBN: 978-1-4612-8648-6

  • Online ISBN: 978-1-4612-4092-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation